Adrian Adams - Aug 18, 2021 Form 4 Insider Report for IMPEL NEUROPHARMA INC (IMPL)

Role
COB, CEO and President, Director
Signature
/s/ John Leaman, M.D. as attorney-in-fact
Stock symbol
IMPL
Transactions as of
Aug 18, 2021
Transactions value $
$279,790
Form type
4
Date filed
8/19/2021, 05:23 PM
Previous filing
Jul 26, 2021
Next filing
Jan 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMPL Common Stock Purchase $238K +17.2K $13.81* 17.2K Aug 18, 2021 Direct F1
transaction IMPL Common Stock Purchase $32.8K +2.2K +12.77% $14.91* 19.4K Aug 18, 2021 Direct F2
transaction IMPL Common Stock Purchase $9.53K +600 +3.09% $15.89* 20K Aug 18, 2021 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.61 to $14.435 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.69 to $15.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.81 to $15.91 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.